CompletedNCT01529515
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
Medication studyAges 18–70Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- Little Rock and 52 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 509
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Colombia, Malaysia, ...
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT01529515
- Official title
Show the full official title
A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects With Schizophrenia
Get this study by email
Recruitment & locations
CompletedLittle Rock, United States · San Fran Cisco, United States · Washington D.C., United States
51 more locations
- Lauderhill, United States
- Chicago, United States
- Hoffman Estates, United States
- Topeka, United States
- Baltimore, United States
- Flowood, United States
- Marlton, United States
- Cedarhurst, United States
- Oklahoma City, United States
- Austin, United States
- Dallas, United States
- Salt Lake City, United States
- Barranquilla, Colombia
- Bogotá, Colombia
- Medellín, Colombia
- Pereira, Colombia
- Johor Bahru, Malaysia
- Kuala Lumpur, Malaysia
- Tanjong Rambutan, Malaysia
- Guadajalara, Mexico
- Mexico City, Mexico
- Monterrey, Mexico
- San Luis Potosí City, Mexico
- Zapopan, Mexico
- Arad, Romania
- Craiova, Romania
- Iași, Romania
- Sibiu, Romania
- Tg Mures, Romania
- Deajun, South Korea
- Gyeongsangnam-Do, South Korea
- Incheon, South Korea
- Seongnam, South Korea
- Diyarbakır, Türkiye
- Sakarya, Türkiye
- Donetsk, Ukraine
- Evpatoriya, Ukraine
- Hlevakha, Ukraine
- Ivano-Frankivsk, Ukraine
- Kerch, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kiev, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Smila, Ukraine
- Ternopil, Ukraine
- Uzhhorod, Ukraine
- Vinnitsa, Ukraine
- Türkiye
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq. and Placebo (20% Intralipid emulsion).
Who was this study for?
Listed age limits: 18 years to 70 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia